X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (10733) 10733
Publication (983) 983
Book Chapter (132) 132
Book Review (106) 106
Conference Proceeding (38) 38
Dissertation (10) 10
Magazine Article (9) 9
Paper (6) 6
Book / eBook (5) 5
Web Resource (5) 5
Data Set (3) 3
Government Document (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (6396) 6396
index medicus (4825) 4825
animals (3910) 3910
male (3041) 3041
diabetes mellitus, type 2 - drug therapy (2385) 2385
female (2357) 2357
dipeptidyl peptidase 4 - metabolism (1762) 1762
dipeptidyl-peptidase iv inhibitors - therapeutic use (1742) 1742
type 2 diabetes (1707) 1707
endocrinology & metabolism (1684) 1684
middle aged (1521) 1521
diabetes (1498) 1498
hypoglycemic agents - therapeutic use (1483) 1483
rats (1450) 1450
biochemistry & molecular biology (1415) 1415
glucagon-like peptide-1 (1412) 1412
mice (1346) 1346
pharmacology & pharmacy (1227) 1227
aged (1143) 1143
adult (1130) 1130
dipeptidyl-peptidase iv inhibitors - pharmacology (981) 981
sitagliptin (961) 961
dipeptidyl peptidase 4 (935) 935
dipeptidyl peptidase-iv (896) 896
glucose (889) 889
dipeptidyl-peptidases and tripeptidyl-peptidases - metabolism (876) 876
expression (868) 868
analysis (861) 861
dipeptidyl peptidase-4 inhibitor (853) 853
dipeptidyl peptidase iv (842) 842
treatment outcome (758) 758
research (735) 735
diabetes mellitus, type 2 - blood (726) 726
dipeptidyl-peptidase iv inhibitors - adverse effects (722) 722
insulin (717) 717
metformin (701) 701
diabetes mellitus (700) 700
amino acid sequence (697) 697
dipeptidyl-peptidase-iv (683) 683
molecular sequence data (679) 679
adamantane - analogs & derivatives (673) 673
cell biology (671) 671
glycemic control (661) 661
hypoglycemic agents (656) 656
double-blind (653) 653
cd26 (642) 642
blood glucose - metabolism (640) 640
immunology (639) 639
care and treatment (606) 606
hypoglycemic agents - adverse effects (606) 606
peptidase (604) 604
peptides (583) 583
hypoglycemic agents - pharmacology (561) 561
sitagliptin phosphate (547) 547
drug therapy, combination (546) 546
vildagliptin (543) 543
proteins (539) 539
enzymes (537) 537
dipeptidyl-peptidase iv inhibitors - administration & dosage (534) 534
dipeptidyl peptidase-4 inhibitors (532) 532
blood glucose - drug effects (516) 516
risk factors (516) 516
dipeptidyl peptidase 4 - genetics (503) 503
type-2 diabetes-mellitus (494) 494
type 2 diabetes mellitus (490) 490
hypoglycemic agents - administration & dosage (483) 483
internal medicine (474) 474
medicine, research & experimental (474) 474
glp-1 (473) 473
chemistry, medicinal (464) 464
drug therapy (462) 462
proteases (456) 456
safety (454) 454
kinetics (448) 448
glucagon (443) 443
physiological aspects (441) 441
dextrose (435) 435
health aspects (432) 432
inhibitors (432) 432
diabetes therapy (420) 420
efficacy (420) 420
substrate specificity (420) 420
metformin - therapeutic use (415) 415
diabetes mellitus, type 2 - complications (414) 414
dipeptidyl peptidase 4 - blood (414) 414
medicine, general & internal (411) 411
beta-cell function (408) 408
inflammation (400) 400
cells, cultured (393) 393
diabetes mellitus, type 2 - metabolism (393) 393
mice, inbred c57bl (387) 387
dipeptidyl-peptidase iv inhibitors (386) 386
dpp-4 inhibitor (378) 378
dipeptidyl peptidase 4 - chemistry (374) 374
abridged index medicus (372) 372
activation (372) 372
article (372) 372
glycated hemoglobin a - metabolism (372) 372
time factors (372) 372
adamantane - therapeutic use (370) 370
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (10548) 10548
German (62) 62
French (41) 41
Russian (38) 38
Korean (37) 37
Spanish (31) 31
Czech (27) 27
Hungarian (15) 15
Polish (15) 15
Italian (8) 8
Japanese (8) 8
Dutch (6) 6
Croatian (4) 4
Danish (4) 4
Norwegian (3) 3
Portuguese (3) 3
Swedish (3) 3
Ukrainian (2) 2
Serbian (1) 1
Slovak (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature, ISSN 0028-0836, 03/2013, Volume 495, Issue 7440, pp. 251 - 254
Journal Article
Journal Article
Journal Article
Journal of Pharmacology and Experimental Therapeutics, ISSN 0022-3565, 02/2012, Volume 340, Issue 2, pp. 248 - 255
Dipeptidyl peptidase (DPP) IV inhibitors are probably beneficial for preventing diabetic complication and modulating glucagon-like peptide-1 receptor (GLP-1R)... 
FIBROSIS | GROWTH-FACTOR-BETA | TGF-BETA | GLP-1 | GLUCAGON-LIKE PEPTIDE-1 | GLUCOSE-METABOLISM | BETA-CELL APOPTOSIS | RECEPTOR EXPRESSION | IMPROVES | PHARMACOLOGY & PHARMACY | NEPHROPATHY | Diabetes Mellitus, Experimental - drug therapy | Dipeptidyl Peptidase 4 - metabolism | Gene Expression - drug effects | Kidney - pathology | Gene Expression - genetics | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Glycated Hemoglobin A - metabolism | Transforming Growth Factor beta1 - metabolism | Caspase 3 - metabolism | Body Weight - drug effects | Diabetic Nephropathies - drug therapy | Pyrrolidines - administration & dosage | Glucagon-Like Peptide 1 - blood | Male | Insulin - blood | Dipeptidyl-Peptidase IV Inhibitors - pharmacology | Pyrrolidines - pharmacology | Pyrrolidines - therapeutic use | Kidney - metabolism | Diabetic Nephropathies - physiopathology | Glomerular Basement Membrane - pathology | Adamantane - therapeutic use | Diabetes Mellitus, Experimental - complications | Adamantane - administration & dosage | Cyclic AMP - urine | Deoxyguanosine - analogs & derivatives | Kidney - physiopathology | Adamantane - analogs & derivatives | Diabetes Mellitus, Experimental - physiopathology | Receptors, Glucagon - genetics | Adamantane - pharmacology | Diabetic Nephropathies - pathology | Kidney - drug effects | Deoxyguanosine - urine | Diabetic Nephropathies - metabolism | Rats | Receptors, Glucagon - metabolism | Rats, Sprague-Dawley | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Blood Glucose - drug effects | Eating - drug effects | Glomerular Basement Membrane - drug effects | Animals | Glucagon-Like Peptide-1 Receptor | Diabetes Mellitus, Experimental - pathology | Blood Glucose - metabolism
Journal Article
Circulation, ISSN 0009-7322, 11/2011, Volume 124, Issue 21, pp. 2338 - 2349
Background-Dipeptidyl-peptidase 4 (DPP-4) inhibitors are increasingly used to accomplish glycemic targets in patients with type II diabetes mellitus. Because... 
adenosine | atherosclerosis | nitric oxide | diabetes mellitus | monocyte chemoattractant proteins | inflammation | GLYCEMIC CONTROL | CARDIAC & CARDIOVASCULAR SYSTEMS | ADENOSINE-DEAMINASE | DIET-INDUCED OBESITY | GLUCAGON-LIKE PEPTIDE-1 | HUMAN CD26 | INSULIN-RESISTANCE | PERIPHERAL VASCULAR DISEASE | INDEPENDENT PATHWAYS | GLUCOSE-UPTAKE | HEMATOLOGY | TYPE-2 DIABETES-MELLITUS | T-CELLS | Inflammation - pathology | Apolipoproteins E - deficiency | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Male | Dipeptidyl-Peptidase IV Inhibitors - pharmacology | Cell Movement - physiology | Uracil - pharmacology | Chemotaxis - physiology | Piperidines - pharmacology | Time Factors | Insulin Resistance - physiology | Metabolism - drug effects | Monocytes - pathology | Receptors, LDL - deficiency | Blood Pressure - drug effects | Disease Models, Animal | Receptors, LDL - genetics | Atherosclerosis - pathology | Atherosclerosis - physiopathology | Uracil - therapeutic use | Chemotaxis - drug effects | Mice, Knockout | Animals | Piperidines - therapeutic use | Apolipoproteins E - genetics | Glucose - metabolism | Inflammation - prevention & control | Mice | Atherosclerosis - prevention & control | Inflammation - physiopathology | Uracil - analogs & derivatives | Care and treatment | Enzyme inhibitors | Research | Proteases | Atherosclerosis
Journal Article
Journal Article
Cardiovascular Research, ISSN 0008-6363, 10/2012, Volume 96, Issue 1, pp. 140 - 149
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 04/2016, Volume 18, Issue 4, pp. 333 - 347
Type 2 diabetes (T2DM) is a progressive disease, and pharmacotherapy with a single agent does not generally provide durable glycaemic control over the long... 
linagliptin | glyburide | incretin | saxagliptin | diabetes mellitus | omarigliptin | anagliptin | gliclazide | glimepiride | sitagliptin | vildagliptin | gemigliptin | alogliptin | antidiabetic drug | glipizide | glycaemic control | trelagliptin | GLP‐1 | glibenclamide | evogliptin | teneligliptin | Glimepiride | Incretin | GLP-1 | Trelagliptin | Diabetes mellitus | Sitagliptin | Glipizide | Evogliptin | Anagliptin | Glyburide | Antidiabetic drug | Omarigliptin | Gliclazide | Alogliptin | Linagliptin | Vildagliptin | Gemigliptin | Glibenclamide | Glycaemic control | Teneligliptin | Saxagliptin | SEVERE HYPOGLYCEMIA | IV INHIBITOR | ENDOCRINOLOGY & METABOLISM | TYPE-2 DIABETES-MELLITUS | INSULIN SECRETAGOGUES | GLYCEMIC CONTROL | CARDIOVASCULAR EVENTS | DPP-4 INHIBITOR | DOUBLE-BLIND | METFORMIN THERAPY | SAVOR-TIMI 53 | Glycated Hemoglobin A - analysis | Hypoglycemia - epidemiology | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Cardiovascular Diseases - prevention & control | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Risk | Hypoglycemia - prevention & control | Cardiovascular Diseases - complications | Hypoglycemic Agents - administration & dosage | Cardiovascular Diseases - epidemiology | Diabetic Cardiomyopathies - prevention & control | Weight Gain - drug effects | Sulfonylurea Compounds - administration & dosage | Diabetic Angiopathies - prevention & control | Sulfonylurea Compounds - pharmacokinetics | Hypoglycemia - chemically induced | Diabetes Mellitus, Type 2 - complications | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Hypoglycemic Agents - pharmacokinetics | Administration, Oral | Sulfonylurea Compounds - therapeutic use | Sulfonylurea Compounds - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Diabetes Mellitus, Type 2 - blood | Dipeptidyl-Peptidase IV Inhibitors - pharmacokinetics |